SquareMind, a developer of AI and robotics solutions for dermatology, has raised $18 million in funding, including previously undisclosed pre-Series A financing, to bring its Swan robotic skin imaging platform to market. The round was led by Sonder Capital, with participation from the Deeptech 2030 Fund, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and others.
Key takeaways
- Swan is described as the world’s first robot to capture standardized, full-body dermoscopic skin imaging, providing a view of the entire skin surface at a level typically seen when examining moles up close.
- The automated imaging process takes only minutes and integrates into clinical workflows, with AI-based software supporting review of skin imaging to track new or changing moles over time while physicians retain full clinical judgment.
- The funding will support commercial, engineering, and customer support team growth ahead of a near-term launch in the U.S. and Europe, where demand for skin exams is high and rising.
Skin screening is the number-one volume procedure in dermatology, and demand outpaces capacity due to an aging population, with waitlists stretching months. Time constraints limit thorough documentation, which is critical for early detection, as 80% of melanomas are new lesions. SquareMind’s technology aims to reduce cognitive load and fatigue for dermatologists, optimize their time, and support comprehensive documentation so they can focus on patient care.
Source: Robotics & Automation News (roboticsandautomationnews.com) · Published 2026-04-27 · “Squaremind raises $18 million to redefine skin exams with robotics and AI”